Advances in Left Ventricular Assist Devices and Mechanical Circulatory Support

Desai, Suneel Ramesh; Hwang, Nian Chih

doi:10.1053/j.jvca.2018.01.026

Cited by 16 publications

(10 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 There has been significant progress in improving clinical outcome sin patients with heart failure who require mechanical circulatory support with a left ventricular assist device. 62 Despite 3 generations of these devices, there are still clinical challenges, including the risks of stroke, right ventricular failure, and perioperative coagulopathy. [62][63][64] The ongoing advances with these lifesaving devices will also pose unique considerations for these patients in the setting of noncardiac surgery.…”

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 99%

“…62 Despite 3 generations of these devices, there are still clinical challenges, including the risks of stroke, right ventricular failure, and perioperative coagulopathy. [62][63][64] The ongoing advances with these lifesaving devices will also pose unique considerations for these patients in the setting of noncardiac surgery. 65,66 It is likely that further refinements in this technology will result in increasing diffusion of these devices throughout clinical practice.…”

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 99%

See 1 more Smart Citation

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2019

Evans¹,

Weiner

Shaefi

et al. 2020

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

This highlights in our specialty for 2019 begin with the ongoing major developments in transcatheter valve interventions. Thereafter, the advances in left ventricular assist devices are reviewed. The recent focus on conduit selection and robotic options in coronary artery bypass surgery are then explored. Finally, this special articles closes with a discussion of pulmonary hypertension in noncardiac surgery, anesthetic technique in cardiac surgery, as well as postoperative pneumonia and its outcome consequences.

show abstract

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 99%

Section: Transcatheter Mitral Valve Replacementmentioning

confidence: 99%

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2019

Evans¹,

Weiner

Shaefi

et al. 2020

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

show abstract

“…Cardiovascular diseases are leading causes of death and medical expenditure worldwide even recent progresses in medical treatments [1]. Therapeutic modalities in severe heart diseases should be further investigated considering that chances in heart transplantation are quite limited due to donor shortage [2], and ventricular assist devices for circulatory support are not anticipated for long-term use due to complications such as thromboembolism, hemorrhage, and infection so far [3,4]. Regenerative medicine is an emerging therapeutic option to provide new approaches in current cardiovascular medicine [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Strategies for immune regulation in iPS cell-based cardiac regenerative medicine

et al. 2020

View full text Add to dashboard Cite

Cardiac regenerative therapy is expected to be a promising therapeutic option for the treatment of severe cardiovascular diseases. Artificial tissues or organoids made from cardiovascular cell lineages differentiated from human induced pluripotent stem cells (iPSCs) are expected to regenerate the damaged heart. Even though immune rejection rarely occurs when iPSC-derived graft and the recipient have the same HLA type, in some cases, such as tissue transplantation onto hearts, the HLA matching would not be sufficient to fully control immune rejection. The present review introduces recent immunomodulatory strategies in iPSC-based transplantation therapies other than MHC matching including the induction of immune tolerance through iPSC-derived antigen-presenting cells, simultaneous transplantation of syngeneic mesenchymal stem cells, and using the universal donor cells such as gene editing-based HLA modulation in iPSCs to regulate T cell compatibility. In addition, we present future perspectives for proper adjustment of immunosuppression therapy after iPSC-derived tissue/organoid-based cardiac regenerative therapies by identifying biomarkers monitoring immune rejection.

show abstract

“…1 Modifications to either insertion or device design also have been developed because of a desire to increase mobility, reduce cost, and optimize comfort. 2 Intra-aortic balloon pump (IABP) and right ventricular assist device are 2 such mechanical support devices. An IABP is usually placed through the femoral artery to improve diastolic coronary flow (with balloon inflation) and reduce afterload (with deflation) to aid the failing heart.…”

mentioning

confidence: 99%

“…5 The drainage occurs from the right atrial orifice, and ejection occurs in the PA. Malposition of the device can cause several life-threatening complications, such as arrhythmias and acute right ventricular (RV) overload. 2 The authors present 2 cases, one in which the tip of an IABP inserted through the axillary artery migrated into the left ventricle and the other in which the tip of the TPD migrated back into the right ventricle.…”

mentioning

confidence: 99%